Literature DB >> 11494145

Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.

J J Kim1, J S Yang, L K Nottingham, W Tang, K Dang, K H Manson, M S Wyand, D M Wilson, D B Weiner.   

Abstract

Prostate specific antigen (PSA) is a widely used marker for prostate cancer, which is secreted by normal prostate cells at low levels, but is produced more substantially by cancer cells. We have previously reported on the use of a DNA vaccine construct that encodes for human PSA gene to elicit host immune responses against cells producing PSA. DNA immunization strategy delivers DNA constructs encoding for a specific immunogen into the host, who becomes the in vivo protein source for the production of antigen. This antigen then is the focus of the resulting immune response. In this study, we examine the induction of immune responses and safety profiles in rhesus macaques immunized with DNA-based PSA vaccine. We observed induction of PSA-specific humoral response as well as positive PSA-specific lymphoproliferative (LPA) response in the vaccinated macaques. We also observed that the stimulated T cells from the PSA-immunized rhesus macaques produced higher levels of Th1 type cytokine IFN-gamma than the control vector immunized animals. On the other hand, DNA immunization did not result in any adverse effects in the immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and renal chemistries. The macaques appeared healthy, without any physical signs of toxicity throughout the observation period. In addition, we did not observe any adverse effect on the vaccination site. The apparent safety and immunogenecity of DNA immunization in this study suggest that further evaluation of this vaccination strategy is warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494145     DOI: 10.1038/sj.onc.1204542

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.

Authors:  Sarfraz Ahmad; Garrett Casey; Paul Sweeney; Mark Tangney; Gerald C O'Sullivan
Journal:  Genet Vaccines Ther       Date:  2010-02-05

Review 2.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

Review 3.  Advances in prostate cancer immunotherapies.

Authors:  Michael Basler; Marcus Groettrup
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection.

Authors:  Jens Encke; Jomo Bernardin; Jasmin Geib; Gocha Barbakadze; Raymond Bujdoso; Wolfgang Stremmel
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

5.  A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Authors:  M Pavlenko; A-K Roos; A Lundqvist; A Palmborg; A M Miller; V Ozenci; B Bergman; L Egevad; M Hellström; R Kiessling; G Masucci; P Wersäll; S Nilsson; P Pisa
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.